Kiwetinohk Energy Valuation
Is Y9B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of Y9B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Y9B (€9.7) is trading above our estimate of fair value (€3.46)
Significantly Below Fair Value: Y9B is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for Y9B?
Other financial metrics that can be useful for relative valuation.
| What is Y9B's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CA$625.84m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.8x |
| Enterprise Value/EBITDA | 3.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does Y9B's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.1x | ||
DR0 Deutsche Rohstoff | 2.6x | -13.5% | €180.6m |
ETG EnviTec Biogas | 9x | n/a | €450.0m |
VH2 Friedrich Vorwerk Group | 29.5x | 24.6% | €488.0m |
CE2 CropEnergies | 15.3x | -7.5% | €1.0b |
Y9B Kiwetinohk Energy | 30.9x | n/a | €625.8m |
Price-To-Earnings vs Peers: Y9B is expensive based on its Price-To-Earnings Ratio (30.9x) compared to the peer average (14.1x).
Price to Earnings Ratio vs Industry
How does Y9B's PE Ratio compare vs other companies in the European Oil and Gas Industry?
Price-To-Earnings vs Industry: Y9B is expensive based on its Price-To-Earnings Ratio (30.9x) compared to the European Oil and Gas industry average (8.3x).
Price to Earnings Ratio vs Fair Ratio
What is Y9B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 30.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate Y9B's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €9.70 | €12.37 +27.6% | 16.1% | €15.05 | €9.36 | n/a | 6 |
| Sep ’25 | €9.75 | €12.56 +28.8% | 15.9% | €14.87 | €9.25 | n/a | 7 |
| Aug ’25 | €8.95 | €12.69 +41.8% | 15.9% | €15.03 | €9.35 | n/a | 7 |
| Jul ’25 | €8.80 | €12.94 +47.0% | 16.0% | €15.38 | €9.57 | n/a | 7 |
| Jun ’25 | €8.85 | €12.86 +45.4% | 15.9% | €15.18 | €9.45 | n/a | 8 |
| May ’25 | €8.35 | €12.97 +55.4% | 16.7% | €15.42 | €9.59 | n/a | 8 |
| Apr ’25 | €7.95 | €12.49 +57.1% | 15.8% | €14.91 | €9.49 | n/a | 7 |
| Mar ’25 | €7.30 | €12.85 +76.0% | 16.1% | €14.99 | €9.54 | n/a | 7 |
| Feb ’25 | €7.60 | €12.86 +69.2% | 16.1% | €15.00 | €9.55 | n/a | 7 |
| Jan ’25 | €7.55 | €13.32 +76.4% | 18.4% | €16.40 | €9.56 | n/a | 7 |
| Dec ’24 | €8.60 | €13.08 +52.1% | 15.2% | €16.04 | €10.70 | n/a | 8 |
| Nov ’24 | €8.85 | €13.57 +53.3% | 18.2% | €16.35 | €10.90 | n/a | 6 |
| Oct ’24 | €8.90 | €14.51 +63.1% | 21.0% | €18.46 | €11.15 | €9.35 | 6 |
| Sep ’24 | €8.70 | €14.38 +65.3% | 20.2% | €18.15 | €10.96 | €9.75 | 6 |
| Aug ’24 | €9.50 | €14.42 +51.8% | 20.2% | €18.20 | €10.99 | €8.95 | 6 |
| Jul ’24 | €8.25 | €14.30 +73.4% | 21.9% | €18.34 | €11.07 | €8.80 | 6 |
| Jun ’24 | €8.75 | €14.40 +64.6% | 20.2% | €18.17 | €10.97 | €8.85 | 6 |
| May ’24 | €8.25 | €14.91 +80.8% | 18.7% | €18.03 | €10.89 | €8.35 | 6 |
| Apr ’24 | €7.90 | €15.28 +93.4% | 14.8% | €17.93 | €12.18 | €7.95 | 6 |
| Mar ’24 | €8.70 | €16.07 +84.7% | 11.4% | €18.32 | €13.82 | €7.30 | 6 |
| Feb ’24 | €9.65 | €16.09 +66.8% | 10.8% | €18.21 | €13.74 | €7.60 | 6 |
| Jan ’24 | €9.70 | €16.31 +68.2% | 10.1% | €18.33 | €13.83 | €7.55 | 6 |
| Dec ’23 | €10.20 | €17.07 +67.3% | 10.1% | €19.18 | €14.47 | €8.60 | 6 |
| Nov ’23 | €12.70 | €17.83 +40.4% | 11.6% | €20.43 | €14.86 | €8.85 | 6 |
| Oct ’23 | €10.30 | €18.31 +77.7% | 10.3% | €20.80 | €15.89 | €8.90 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.